News | October 11, 2023
AstraZeneca’s Tagrisso to lead lung cancer small molecule market with over $7 billion sales by 2029, says GlobalData
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by respiratory syncytial virus
Currently, Praveen Akkinepally is the Head of Lung Cancer Commercialization, AstraZeneca Gaithersburg, MD, USA
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The receipt of this permission paves way for the launch of Trastuzumab deruxtecan (Enhertu) solution of 100mg/5mL in India
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Subscribe To Our Newsletter & Stay Updated
